0      0

2020 Annual Meeting


AM20-69 - AM20-69: Benefit-Risk Assessment to Inform FDA Regulatory Decisions


Oct 5, 2020 9:00pm ‐ Oct 5, 2020 9:00pm


Credits: None available.

Standard: $25.00
Members: $20.00

Description

The FDA makes decisions about imminent risks to the blood supply and evaluates potential risk mitigation using a benefit-risk approach in order to inform policy. How is this done? What parameters structure these decisions and what are the processes invoked to incorporate them? This session will describe FDA’s structured regulatory decision-making process using real benefit-risk assessment examples and provide opportunities for audience participation (ARS). Speakers will engage the audience by describing how results are incorporated into final guidance and final rules. Audience challenge questions will be included. Finally, there will be a demonstration of a risk assessment tool developed by the FDA, BRisk or BenefitRisk, to show how infectious disease risks can be modeled for better understanding of potential disease exposures.

Learning Objectives:
  • Explain the parameters governing the FDA’s process for evaluating benefit and risk of changes to blood safety policy.
  • Describe two examples of the benefits and risks evaluated for incorporation into FDA policy decisions.
  • Summarize how the BRisk tool can be used to evaluate emerging infectious disease risk.

Speaker(s):

Credits Available


AM20-69: Benefit-Risk Assessment to Inform FDA Regulatory Decisions Evaluation

You must be logged in and own this session in order to post comments.

Print Certificate
Completed on: token-completed_on
Print Transcript
Please select the appropriate credit type:
/
test_id: 
credits: 
completed on: 
rendered in: 
* - Indicates answer is required.
token-content

token-speaker-name
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
token-index
token-content
/
/
token-index
token-content
token-index
token-content